anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: During myocardial ischemia/reperfusion (I/R) injury, high levels of matrix Ca2+ and reactive oxygen species (ROS) induce the opening of the mitochondrial permeability transition pore (mPTP), which causes mitochondrial dysfunction and ultimately necrotic death. However, the mechanisms of how these triggers individually or cooperatively open the pore have yet to be determined.
METHODS: Here, we use a combination of isolated mitochondrial assays and in vivo I/R surgery in mice. We challenged isolated liver and heart mitochondria with Ca2+, ROS, and Fe2+ to induce mitochondrial swelling. Using inhibitors of the mPTP (cyclosporine A or ADP) lipid peroxidation (ferrostatin-1, MitoQ), we determined how the triggers elicit mitochondrial damage. Additionally, we used the combination of inhibitors during I/R injury in mice to determine if dual inhibition of these pathways is additivity protective.
RESULTS: In the absence of Ca2+, we determined that ROS fails to trigger mPTP opening. Instead, high levels of ROS induce mitochondrial dysfunction and rupture independently of the mPTP through lipid peroxidation. As expected, Ca2+ in the absence of ROS induces mPTP-dependent mitochondrial swelling. Subtoxic levels of ROS and Ca2+ synergize to induce mPTP opening. Furthermore, this synergistic form of Ca2+- and ROS-induced mPTP opening persists in the absence of CypD (cyclophilin D), suggesting the existence of a CypD-independent mechanism for ROS sensitization of the mPTP. These ex vivo findings suggest that mitochondrial dysfunction may be achieved by multiple means during I/R injury. We determined that dual inhibition of the mPTP and lipid peroxidation is significantly more protective against I/R injury than individually targeting either pathway alone.
CONCLUSIONS: In the present study, we have investigated the relationship between Ca2+ and ROS, and how they individually or synergistically induce mitochondrial swelling. Our findings suggest that Ca2+ mediates mitochondrial damage through the opening of the mPTP, although ROS mediates its damaging effects through lipid peroxidation. However, subtoxic levels both Ca2+ and ROS can induce mPTP-mediated mitochondrial damage. Targeting both of these triggers to preserve mitochondria viability unveils a highly effective therapeutic approach for mitigating I/R injury.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention concerns veterinary science. The invention discloses administration of Arg-Pro-Gly-Pro tetrapeptide as an agent for prevention and treatment of viral diseases. A pharmaceutical composition for prevention and treatment of viral diseases contains an aqueous solution of Arg-Pro-Gly-Pro tetrapeptide in concentration 0.1-1 % and Nipagin in a certain relation of ingredients. A method for prevention of viral diseases involves intranasal, oral or intraperitoneal introduction of said pharmaceutical composition in a dose 0.2-5 mg a day per a mouse for 2 days. A method for treatment of viral diseases involves intranasal, oral or intraperitoneal introduction of said pharmaceutical composition in a dose 0.2-5 mg a day per a mouse for 3 days. ^ EFFECT: invention enables extending the range of antiviral drugs, providing higher clinical and preventive effectiveness in viral infections, reducing drug cost. ^ 4 cl, 4 tbl, 1 ex
Parkinson's disease (PD) is a complex neurological disease that affects \~6.1 million people worldwide - mostly older adults \>60 years. The most effective treatment for PD is dopaminergic therapy, particularly levodopa (Ldopa). People with PD have variable responses to Ldopa, including degrees of motor fluctuations (MF) throughout the day. The half-life of Ldopa is \~1.5 h and therefore, dosage and timing are essential to mitigate MF. Ldopa is a large neutral amino acid (LNAA), and the bioavailability of Ldopa is compromised when simultaneously ingested with LNAA (e.g., leucine). Both Ldopa and LNAAs from food are absorbed through the same intestinal transporter, but LNAAs from food are preferentially absorbed by the enterocyte, limiting the bioavailability of Ldopa. Thus, the scientific community often recommends the protein-redistribution diet (PRD). With PRD, patients limit protein (\<10 g) at the desired time of medication efficacy (daytime) and meet their protein needs during the evening meal (\~70+g). There are deleterious implications of the PRD for older adults with PD; consumption of \>30 g of protein, in a single meal, will not sufficiently increase muscle protein synthesis. Additionally, the impact of the PRD on skeletal muscle quality and function has not been determined, and it is unclear, based on prior studies, whether the PRD enhanced drug absorption. Therefore, the objective of this study is to address these gaps in knowledge. This study will quantify the effects of dietary protein pattern on skeletal muscle in PD; determine the effects of dietary protein pattern on sleep quality in PD. This study is an acute, 5-week, crossover intervention with PD participants randomly assigned to first adhere to either the PCD or PRD. Participants will receive diet prescriptions and meal plans for their respective diet, and outcome measures will be assessed at days 0, 14, 21, and 35.
The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli.
NEW MATERIAL:An aminomethylphosphonic acid derivative of formulaI(R is lower alkyl other than groups characteristic in the aminoacids constituting protein, phenyl, heterocyclic ring). EXAMPLE:2-Thienylalanylaminomethylphosphonic acid. USE:Antibiotic showing strong effect against gram-positive and -negative bacteria of various kinds. The combination thereof with another antibiotic develops pharamacologically synergic effect. PREPARATION:A protected aminoacid of formula II (R' is H, lower alkyl; A is amino-protecting group) or its reactive derivative and aminomethylphosphonic acid of formula III or its ester are subjected to condensation reaction to produce an amide of formula IV. Then, the product is deprotected, when necessary, the part of the phosphoric ester is hydrolyzed to give the compound of formulaI.
Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation, sweating and spontaneous movements of the patient. As an orientation anesthesiologists are advised to administer 5 µg sufentanil if systolic blood pressure is \> 140 mmHg or mean blood pressure is \> 100 mmHg or heart rate is \> 90 /min. If assessed necessary, the anaesthesiologists are allowed to administer higher or lower sufentanil doses up to their discretion.
A method of handling an adhesive laminate, wherein the adhesive laminate is provided releasably adhered to a first web, comprising a plurality of cut or punched sections and wherein adjacent sections of the adhesive laminate remain joined to one another in the longitudinal direction of the web through one or more tie points. A first supporting structure and a second supporting structure adjacent to the first supporting structure are provided. The first web is led over the first supporting structure. A second web is provided and led over the second supporting structure, wherein the second web is oriented such that the release surface of the second web faces the first supporting structure. A leading portion of a first section of adhesive laminate from the first web is attached to the release surface of the second web and the second web is advanced such that the first section of the adhesive laminate is detached from a second section of adhesive laminate and the leading edge of the second section of adhesive laminate is adhered to the second web in a spaced apart configuration from the trailing edge of the first section of the adhesive laminate. A transdermal drug delivery device prepared by such a method.
The invention provides clonidine formulations in a biodegradable polymer carrier. Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
A carbon material for contaminant removal performance. The carbon material has an equilibrium pH (pH) between about 1.5 and about 9 eq ) A Total Acidic Functionality (TAF) between about 0.8 and about 3mequiv./g-C, and a cation adsorption capacity greater than about 70 cmmol/kg-C. By determining the pH of the carbon material in contact with the electrolyte solution eq Carbon materials are identified. TAF was quantified by acid-base titration to identify carbon materials. The carbon material was identified by generating a proton binding curve according to acid-base titration. Carbon materials were identified by integrating f (pk) calculated from proton binding curves. By passingEquilibrium isotherms were determined and the data were converted to cation adsorption capacity to identify carbon materials. The carbon material is identified by comparing the cation adsorption capacity of the carbon material with a predetermined range of cation adsorption capacities.
BACKGROUND: Loss of dopaminergic neurons underlies the motor symptoms of Parkinson's disease (PD). However stereotypical PD symptoms only manifest after approximately 80% of dopamine neurons have died making dopamine-related motor phenotypes unreliable markers of the earlier stages of the disease. There are other non-motor symptoms, such as depression, that may present decades before motor symptoms.
METHODS: Because serotonin is implicated in depression, here we use niche, fast electrochemistry paired with mathematical modelling and machine learning to, for the first time, robustly evaluate serotonin neurochemistry in vivo in real time in a toxicological model of Parkinsonism, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
RESULTS: Mice treated with acute MPTP had lower concentrations of in vivo, evoked and ambient serotonin in the hippocampus, consistent with the clinical comorbidity of depression with PD. These mice did not chemically respond to SSRI, as strongly as control animals did, following the clinical literature showing that antidepressant success during PD is highly variable. Following L-DOPA administration, using a novel machine learning analysis tool, we observed a dynamic shift from evoked serotonin release in the hippocampus to dopamine release. We hypothesize that this finding shows, in real time, that serotonergic neurons uptake L-DOPA and produce dopamine at the expense of serotonin, supporting the significant clinical correlation between L-DOPA and depression. Finally, we found that this post L-DOPA dopamine release was less regulated, staying in the synapse for longer. This finding is perhaps due to lack of autoreceptor control and may provide a ground from which to study L-DOPA induced dyskinesia.
CONCLUSIONS: These results validate key prior hypotheses about the roles of serotonin during PD and open an avenue to study to potentially improve therapeutics for levodopa-induced dyskinesia and depression.
PROBLEM TO BE SOLVED: To provide a medical information display system capable of easily performing display control suitable for a situation of a portable terminal is positioned.SOLUTION: The medical information display system comprises: a positional information calculation section; a storage; an identification section; a search section; and a display controller. The positional information calculation section calculates a piece of positional information representing a present position of a portable terminal. The storage stores plural applications which are associated with respective rooms in a hospital for setting the type of medical information for displaying on a display device, and setting information for setting a display mode of a piece of medical information to be displayed by the application. The identification section receives the positional information and identifies a room where the portable terminal is positioned. The search section searches the storage for an application associated with the identified room. The display controller controls to execute the searched application and to display the medical information on the display device using a predetermined display mode based on the setting information.
BACKGROUND: Abdominal aortic calcification (AAC) pathogenesis is intricately linked with inflammation. The pan-immune-inflammation value (PIV) emerges as a potential biomarker, offering reflection into systemic inflammatory states and assisting in the prognosis of diverse diseases. This research aimed to explore the association between PIV and AAC.
METHODS: Employing data from the National Health and Nutrition Examination Survey (NHANES), this cross-sectional analysis harnessed weighted multivariable regression models to ascertain the relationship between PIV and AAC. Trend tests probed the evolving relationship among PIV quartiles and AAC. The study also incorporated subgroup analysis and interaction tests to determine associations within specific subpopulations. Additionally, the least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression were used for characteristics selection to construct prediction model. Nomograms were used for visualization. The receiver operator characteristic (ROC) curve, calibration plot and decision curve analysis were applied for evaluate the predictive performance.
RESULTS: From the cohort of 3,047 participants, a distinct positive correlation was observed between PIV and AAC. Subsequent to full adjustments, a 100-unit increment in PIV linked to an elevation of 0.055 points in the AAC score (β=0.055, 95% CI: 0.014-0.095). Categorizing PIV into quartiles revealed an ascending trend: as PIV quartiles increased, AAC scores surged (β values in Quartile 2, Quartile 3, and Quartile 4: 0.122, 0.437, and 0.658 respectively; P for trend <0.001). Concurrently, a marked rise in SAAC prevalence was noted (OR values for Quartile 2, Quartile 3, and Quartile 4: 1.635, 1.842, and 2.572 respectively; P for trend <0.01). Individuals aged 60 or above and those with a history of diabetes exhibited a heightened association. After characteristic selection, models for predicting AAC and SAAC were constructed respectively. The AUC of AAC model was 0.74 (95%CI=0.71-0.77) and the AUC of SAAC model was 0.84 (95%CI=0.80-0.87). According to the results of calibration plots and DCA, two models showed high accuracy and clinical benefit.
CONCLUSION: The research findings illuminate the potential correlation between elevated PIV and AAC presence. Our models indicate the potential utility of PIV combined with other simple predictors in the assessment and management of individuals with AAC.
Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
This is a pilot study to evaluate the safety and efficacy of the Kauruna Virtual Reality program for the treatment of chronic low back pain. This study is intended to document the safety and efficacy of the use of virtual reality for the treatment of chronic low back pain. The primary outcome measure will be physical functioning as measured by the PROMIS 6. Secondary outcome measures include patient-reported pain intensity, adverse side effects, disability as measured by the Oswestry Low back disability questionnaire, and mental functioning as assessed using the PHQ-9 and GAD-7. Finally, impact on opioid use in patients on chronic opioids will be assessed by documentation of daily opioid dose in oral morphine equivalents.

Forty adult patients with chronic low back pain who are receiving care through the Penn Pain Medicine Center are eligible to participate in the study. The study will consist of a screening visit, followed by randomization into 1 of 2 study groups. Both study groups will participate in two 20-minute virtual reality sessions a week for 8 weeks. Study group 1 will participate in 20 minutes of mindfulness mediation. Study Group 2 will undergo initial sessions focused on graded motor imagery, followed by sessions focused on graded exposure. Patient-reported outcomes data will be obtained at baseline, then weekly during the 8-week study period, then 4 weeks following completion of the study sessions.
Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
Impure solutions of kallikrein inactivator are purified by treating the impure solution with an aqueous solution of a water-soluble salt of metaphosphoric acid whereby the sparingly soluble complex of the inactivator and salt is precipitated, an excess of the metaphosphate salt being avoided, then separating the precipitated complex and freeing it from the salt to give purified solution.  Preferred soluble salts are metaphosphates of ammonium or alkali metals, and by avoidance of excess is meant that the aqueous salt solution is added only until no further precipitation occurs.  The complex may be freed from the salt by dissolution in a solution containing more than 1% w/v concentration of a salt such as ammonium or sodium chloride or ammonium or alkali metal hydroxide, to decompose it, followed by removal of salts by e.g. dialysis or ion exchange; the pure solution may be lyophilized.  Impure solutions for starting materials are suitable preparations from kallikrein-inactivator-containing animal organs, e.g. paratid or lymph glands, lungs, liver, spleen, or pancreas.
BACKGROUND: Forward prediction of atrial fibrillation (AF) termination is a challenging technical problem of increasing significance due to rising AF presentations to emergency departments worldwide. The ability to non-invasively predict which AF episodes will terminate has important implications in terms of clinical decision-making surrounding treatment and admission, with subsequent impacts on hospital capacity and the economic cost of AF hospitalizations.
METHODS AND RESULTS: MEDLINE, EMCare, CINAHL, CENTRAL, and SCOPUS were searched on 29 July 2023 for articles where an attempt to predict AF termination was made using standard surface ECG recordings. The final review included 35 articles. Signal processing techniques fit into three broad categories including machine learning (n = 14), entropy analysis (n = 12), and time-frequency/frequency analysis (n = 9). Retrospectively processed ECG data was used in all studies with no prospective validation studies. Most studies (n = 33) utilized the same ECG database, which included recordings that either terminated within 1 min or continued for over 1 h. There was no significant difference in accuracy between groups (H(2) = 0.058, p-value = 0.971). Only one study assessed recordings earlier than several minutes preceding termination, achieving 92% accuracy using the central 10 s of paroxysmal episodes lasting up to 174.
CONCLUSIONS: No studies attempted to forward predict AF termination in real-time, representing an opportunity for novel prospective validation studies. Multiple signal processing techniques have proven accurate in predicting AF termination utilizing ECG recordings sourced from a database retrospectively.
This project will examine if enhancing Nitric Oxide (NO) bioavailability increases the rates of arteriovenous fistula (AVF) maturation in end stage renal disease patients requiring vascular access for hemodialysis. To enhance NO bioavailability the study team will utilize a program of forearm exercise training, application of nitroglycerin ointment or both.

Following entry into the study, approximately 4 weeks prior to surgery subjects will undergo a series of non-invasive tests of vascular function in the arm of fistula creation. Following this vascular function testing, subjects will follow the intervention treatment for 4 weeks. After 4 weeks of intervention treatment and prior to surgery, the vascular function analysis will be repeated to determine if the interventions had an effect on arm vascular function. Surgery to create the AVF will follow the second vascular function analysis. A discard sample of the vein used to create the AVF and a blood sample will be collected during surgery to assess potential biologic differences between intervention groups. The interventions will be continued until 4 weeks following surgery. Subjects will be followed to determine if the AVF matured and was successfully used for dialysis.
Adequate vitamin D stores are necessary for skeletal health. Vitamin D deficiency is pronounced in women of child bearing age as well as pregnant women in the United States. This study will provide important information about whether vitamin D supplementation may positively impact the normal physiologic loss of bone mass that is observed during lactation.

Recruitment will begin while subjects are pregnant in order to expedite entry into the study in the immediate post-partum period. If subjects are deemed eligible during pregnancy, contact information to include name, address, expected delivery date and two contact phone numbers will be obtained. Subjects will be contacted two weeks prior to expected delivery date and then again at expected delivery date. Subjects will be followed for a total of 18 months.
A system, a method, and a non-transitory computer program product for generating treatment recommendations based on biomarker values are disclosed. Values of a plurality of biomarkers are received from an application executed on a computing device of a user. A score is generated for each biomarker. An overall heath score is computed for a user by weighting and adding all biomarker scores. A severity associated with each biomarker is computed. A physiological condition associated with the severity of each biomarker is identified. An explanation of the severity of the biomarker and at least one treatment recommendation are generated based on the severity associated with each biomarker. The score for each biomarker, the overall health score, the explanation of the severity, and the at least one treatment recommendation are transmitted to the application executed on the computing device of the user via a communication network.